
Ocgn stock performance has been on a rollercoaster ride, with its stock price fluctuating significantly over the past year.
The company's stock price has dropped by as much as 50% in a single day.
Ocgn's stock has shown impressive growth, increasing by over 200% in a matter of months.
This rapid fluctuation is likely due to the company's involvement in the biotech industry, which is known for its high-risk and high-reward investments.
A fresh viewpoint: S B I Card Share Price
Worth a look: Atmos Energy Stock Quote
Stock Performance Overview
Ocugen Inc's stock performance is quite volatile, with a previous close of $0.731.
The stock has traded between $0.705 and $0.743 in a single day.
Over the past year, the stock has ranged from $0 to $2.
Ocugen Inc has a market capitalization of $212,984,000.
The company's primary exchange is the NASDAQ.
Here's a breakdown of Ocugen Inc's stock performance:
Ocugen Inc's diluted earnings per share (EPS) for the trailing 12 months is -$0.19.
The company's revenue growth year-over-year is 135.3%.
Earnings growth year-over-year is 0%.
The profit margin is 0%.
Readers also liked: Lseg Earnings
Financial Information
Ocugen's revenue for 2023 was $6.04 million, a 142.60% increase from the previous year.
This significant jump in revenue is a promising sign for the company's financial health.
Losses in 2023 were -$63.08 million, a decrease of 27.33% from the previous year.
It's worth noting that a decrease in losses is still a loss, but it's a step in the right direction for the company.
The company's financial performance in 2023 shows some positive trends, but it's essential to keep an eye on the company's future progress.
Here's an interesting read: What Are the Next Big Stock Splits
Company News and Events
Ocugen has held several annual general meetings, with the most recent one scheduled for June 28, 2024.
The company has also released its earnings reports on a quarterly basis, with the most recent one being the Q4 2023 Earnings Release on April 2, 2024.
Here are the dates of Ocugen's annual general meetings:
- June 28, 2024
- June 9, 2023
- June 7, 2022
Past Events
Ocugen has a history of holding Annual General Meetings, with the most recent one taking place on June 28, 2024, and reporting an actual EPS of -0.260 USD.
The company has also released several Earnings Reports, with the most recent one being the Q4 2023 Earnings Release on April 2, 2024, which reported an actual EPS of -0.040 USD.
Ocugen's Earnings Reports have consistently shown a negative EPS, with the exception of the Q4 2022 Earnings Release, which was also reported as -0.100 USD.
Here are the notable Earnings Reports and Annual General Meetings held by Ocugen:
Latest News
Ocugen has announced that its OCU500 treatment will be administered via inhalation and as a nasal spray. This innovative approach aims to provide a more convenient and effective way to deliver the treatment.
The COVID-19 pandemic remains a significant public health threat in the US and around the world. The World Health Organization and other global health authorities continue to monitor the situation closely.
A Phase 1 clinical trial for OCU500 is expected to start soon. This is an important step in the development of the treatment and will help determine its safety and efficacy in humans.
Ocugen has reported impressive results from its previous clinical trials, with 100% of treated evaluable subjects demonstrating improvement or preservation in visual function compared to untreated eyes at both one and two years.
Frequently Asked Questions
Is Ocugen stock expected to rise?
Ocugen stock is expected to rise, with an average price target of $6.25 and forecasts ranging from $4.00 to $8.00. Analysts' predictions suggest potential growth, but it's essential to consider the full context before making investment decisions.
Who owns the most OCGn stock?
Vanguard is the largest shareholder of Ocugen Inc (OCGN) stock. Approximately 75% of OCGN stock is held by retail investors.
Why is Ocugen dropping today?
Ocugen's stock is dropping due to an FDA clinical hold on its COVID-19 vaccine candidate Covaxin, which has halted the study's progress. This development is causing market volatility and concerns about the vaccine's future.
What is the fair value of Ocugen?
The fair value of Ocugen is estimated to be between $2.47 and $10.23 USD, based on the Discounted Cash Flows model. This suggests a significant potential upside from the current market price of $0.85 USD.
Featured Images: pexels.com


